Montmorillonite
As of the edition of 20 October 2026, Montmorillonite is a drug: marketed, first approved in 1988 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Unknown
- Brand name
- Smecta
- First approved
- 25 November 1988 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ipsen
- Registered trials
- 8, 2 stopped early
- Disease areas
- Cancer; Infections; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 4 | 2 | 0 | 1 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 8 |